Sudarshan M K, Giri M S Ananda, Mahendra B J, Venkatesh G M, Sanjay T V, Narayana D H Ashwath, Ravish H S
Anti-rabies Clinic and Rabies Epidemiology Unit, Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India.
Hum Vaccin. 2007 May-Jun;3(3):87-9. doi: 10.4161/hv.3.3.4010. Epub 2007 May 6.
Fourteen pregnant women who received rabies post-exposure prophylaxis (PEP) at the anti-rabies clinic (ARC) of Kempegowda Institute of Medical Sciences (KIMS) were followed up for assessing the safety of modern rabies vaccines and equine rabies immunoglobulin (ERIG) in pregnancy. The women were in the age range of 18-28 years, mostly from urban area (64%) and exposed to suspect rabid dogs (86%). They had received purified vero cell rabies vaccine (Verorab = 8 and Abhayrab = 4), purified chick embryo cell vaccine (Rabipur = 2) by Essen regimen; and equine rabies immunoglobulin (Equirab = 7 and Pasteur anti-rabies serum = 1). None of the pregnant women reported any adverse events to either vaccine or equine rabies immunoglobulin. All had safe vaginal deliveries and in all cases both the mother and the child were found to be healthy and normal.
在 Kempegowda 医学科学研究所（KIMS）的抗狂犬病诊所（ARC）接受狂犬病暴露后预防（PEP）的 14 名孕妇，为评估现代狂犬病疫苗和马狂犬病免疫球蛋白（ERIG）在孕期的安全性而接受了随访。这些女性年龄在 18 - 28 岁之间，大多来自城市地区（64%），且暴露于疑似狂犬病犬只（86%）。她们接受了埃森方案的纯化 vero 细胞狂犬病疫苗（Verorab = 8 例，Abhayrab = 4 例）、纯化鸡胚细胞疫苗（Rabipur = 2 例）；以及马狂犬病免疫球蛋白（Equirab = 7 例，巴斯德抗狂犬病血清 = 1 例）。没有一名孕妇报告疫苗或马狂犬病免疫球蛋白出现任何不良事件。所有孕妇均顺产，且所有病例中母亲和孩子均健康正常。
